Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among HIV-infected Children and Adolescents

Inclusion criteria: * Participants age 10-20 years. * Have a history and/or medical record of HIV infection. * Have a history and/or medical record and/or maternal HIV status confirmed of perinatally acquired HIV infection. * Have virological suppression after receiving ART, defined as plasma HIV RNA less than 400 copies/mL within 12 months prior to screening. * Participants who had been evaluated for BMD (have BMD result) within 1 year prior to entry visit. * Caregivers and/or participants gives written inform consent/assent form. Exclusion criteria: * Participants who have a documented history of bone fracture at any time prior to screening. * Participants who have received any form of calcium greater than 1000 mg/day of elemental calcium at least once within 6 months prior screening. * Participants who have received any form of vitamin D (e.g., ergocalciferol or cholecalciferol) supplementation greater than 400 IU/day at least once within 6 months prior to screening. * Participants who have received any past pharmacologic treatment for low bone density or osteoporosis (e.g., alendronate) at any time prior to screening. * Participants who have a documented history of growth hormone deficiency at any time or using growth hormone within 6 months prior to screening. * Participants who have a documented history of primary hyperparathyroidism, hypoparathyroidism, or cushing syndrome at any time prior to screening. * Participants who have a documented prior history of kidney s…